Outcomes of CML patients treated with ponatinib. (A) OS since ponatinib initiation was significantly better for CP-CML patients compared with AP patients, with a 5-year OS of 76.8% and median OS of 20.8 months, respectively. (B) Overall survival since ponatinib initiation, by SCT status. allo-SCT conferred a significant benefit in AP patients, but the response was not found in CP-CML patients.